Professor John Eisman AO
Senior Principal Research Fellow; Group Leader, Bone Research Program, and Director of Clinical Translation and Advanced Education, Garvan Institute of Medical Research; Professor of Medicine, The University of New South Wales; Staff Endocrinologist, St Vincent's Hospital, Sydney
Email: j.eisman 'at' garvan.org.au
Research Group: Fracture Prevention Clinical Studies, Bone Genetics and Epidemiology
Education
1975 Fellow Royal Australian College of Physicians
1975 PhD University of Melbourne
1971 Member Royal Australian College of Physicians
1967 MBBS First Class Honours, Sydney University
1964 BSc (Medical) First Class Honours, Sydney University
Awards and Honours
1997 Order of Australia
1995 Sir Eric Sussman Award, Royal Australasian College of Physicians
Areas of Interest
Epidemiology and costs of osteoporosis, genetics of osteoporosis, molecular and cell biology of bone, vitamin D receptor, clinical research, bone strength, fracture riskNews
A step towards preventing ‘bone failure’ in Australia
07 Nov 2011
In collaboration with pharmaceutical companies and other stakeholders, Garvan will be running awareness-raising seminars about ‘bone failure’, with separate sessions for members of the public and GPs. The program, known as Health Education for Longer Life in Osteoporosis (HELLO) has its inaugural sessions on 26 and 27 November. Her Excellency Ms Quentin Bryce AC, Governor General of Australia, will be opening the Patient Seminar on 27 November.
An extra 5 years of life an unexpected benefit of osteoporosis treatment
MEDIA RELEASE:
03 Feb 2011
Clinical researchers at Garvan have noted an extraordinary and unexpected benefit of osteoporosis treatment – that people taking bisphosphonates are not only surviving well, better than people without osteoporosis, they appear to be gaining an extra five years of life.
Why measuring absolute risk of fracture could save many broken bones
MEDIA RELEASE:
28 Jul 2009
Garvan scientists stress the importance of measuring a person's absolute risk of fracture when determining their treatment options. Other factors currently determine whether or not the Australian Government will pay for preventative treatment.
